Medtronic (NYSE: MDT) Stock: Analyst Downgrade Contrasts with Strong Financial Performance

Font: Financial Modeling Prep  • Jun 03, 2026

• Analyst Rick Wise of Stifel Nicolaus lowered Medtronic's price target to $80.00 from $95.00, despite the stock trading at $77.95.
• Medtronic achieved its best top-line performance in a decade for Q4 2026, reporting $9.81 billion in quarterly revenue (a 9.90% increase) and $36.40 billion for the full year (an 8.40% increase), significantly boosted by its Cardiac Ablation Solutions business.
• While management forecasts strong organic revenue growth for fiscal year 2027, the EPS guidance of $5.90 to $6.00 falls below the $6.05 analyst consensus, influenced by tariff pressures and MiniMed separation costs.

Medtronic (NYSE: MDT) is a global company that develops and manufactures medical devices and therapies. On June 3, 2026, analyst Rick Wise of Stifel Nicolaus lowered his price target for Medtronic to $80.00 from $95.00. A price target is an analyst's estimate of a stock's future value. This new target implies a 2.63% potential increase from its $77.95 price at the time.

This analyst revision contrasts with the company's recent strong financial results. Medtronic reported its best top-line performance in a decade for its fourth quarter of 2026. The company announced quarterly revenue of $9.81 billion, a 9.90% increase, and full-year revenue of $36.40 billion, an 8.40% increase. The stock price increased by 5.46% after the announcement.

A significant driver of this performance was the Cardiac Ablation Solutions business. As highlighted by Zacks, this segment's revenue surged by 78% globally and 124% in the United States. This growth allowed Medtronic to capture an additional 8 points of market share in the U.S. and puts the segment on track to achieve $2.00 billion in trailing revenue.

Looking forward, management forecasts organic revenue growth between 6.75% and 7.25% for fiscal year 2027. However, the company's full-year earnings per share (EPS) guidance of $5.90 to $6.00 falls short of the $6.05 analyst consensus. This cautious earnings outlook is due to factors like tariff pressures and costs from the MiniMed separation.

Despite the conservative earnings forecast, Medtronic is taking positive steps. The company is making targeted investments in innovation and recently raised its quarterly dividend. It also successfully completed the initial public offering (IPO) for its MiniMed business, establishing it as a separate, publicly traded company.